- Home
- IAC vs HAE Comparison
IAC vs HAE Comparison
Compare IAC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAC
- HAE
- Stock Information
- Founded
- IAC 2019
- HAE 1971
- Country
- IAC United States
- HAE United States
- Employees
- IAC N/A
- HAE N/A
- Industry
- IAC Computer Software: Programming Data Processing
- HAE Medical/Dental Instruments
- Sector
- IAC Technology
- HAE Health Care
- Exchange
- IAC Nasdaq
- HAE Nasdaq
- Market Cap
- IAC 4.1B
- HAE 3.6B
- IPO Year
- IAC 1992
- HAE 1991
- Fundamental
- Price
- IAC $45.66
- HAE $62.98
- Analyst Decision
- IAC Buy
- HAE Strong Buy
- Analyst Count
- IAC 13
- HAE 9
- Target Price
- IAC $65.08
- HAE $103.56
- AVG Volume (30 Days)
- IAC 975.5K
- HAE 1.4M
- Earning Date
- IAC 02-11-2025
- HAE 02-06-2025
- Dividend Yield
- IAC N/A
- HAE N/A
- EPS Growth
- IAC N/A
- HAE 3.20
- EPS
- IAC N/A
- HAE 2.54
- Revenue
- IAC $3,807,233,000.00
- HAE $1,373,515,000.00
- Revenue This Year
- IAC N/A
- HAE $7.56
- Revenue Next Year
- IAC $3.55
- HAE $3.13
- P/E Ratio
- IAC N/A
- HAE $24.82
- Revenue Growth
- IAC N/A
- HAE 8.14
- 52 Week Low
- IAC $39.61
- HAE $58.80
- 52 Week High
- IAC $58.29
- HAE $97.97
- Technical
- Relative Strength Index (RSI)
- IAC 57.56
- HAE 38.28
- Support Level
- IAC $40.91
- HAE $58.80
- Resistance Level
- IAC $48.50
- HAE $65.15
- Average True Range (ATR)
- IAC 1.43
- HAE 2.76
- MACD
- IAC 0.48
- HAE 0.34
- Stochastic Oscillator
- IAC 62.83
- HAE 32.85
About IAC IAC Inc.
IAC is an internet media company with segments that include Angi (33% of total revenue), Dotdash Meredith (39%), search (14%), and emerging and other (14%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.